This post was originally published on this site
https://i-invdn-com.akamaized.net/trkd-images/LYNXMPEH3T08X_L.jpg
(Reuters) – AstraZeneca (NASDAQ:AZN) said on Friday it expected higher sales in the second half of the year, as it reported first-quarter profit and sales ahead of analysts’ average expectations, including $275 million in COVID-19 vaccine sales.
